U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

Pfizer (PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (GSK) patents for its RSV vaccine.

GSK said data from a late-phase study showed that its respiratory syncytial virus vaccine, Arexvy, granted protection over three full RSV seasons.

Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist ...

The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV, which typically causes ...

Arexvy is the world's first approved RSV vaccine and results showed that after a single dose, cumulative efficacy over three full RSV seasons was clinically meaningful.

GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three ...